07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

DI-Leu16-IL2: Phase I/II data

An open-label, dose-escalation, U.S. Phase I/II trial showed that thrice-weekly 0.5, 1 and 2 mg/m 2 subcutaneous DI-Leu16-IL2 every 3 weeks led to tumor regression or stabilization in 12 of 13 evaluable patients with relapsed...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Alopexx Enterprises LLC, Provenance deal

Alopexx and Provenance formed a JV to develop and commercialize Provenance's DI-Leu16-IL2 . Provenance will contribute the compound and Alopexx will contribute $8 million to the JV, which will be named Alopexx Oncology LLC ....